Hormonal
Abnormal adiposity is the dominant causal driver of cardiometabolic disease, and targeting it as the primary intervention simplifies management and reduces the need for concurrent pharmacotherapy for downstream drivers like hypertension and dyslipidemia.
Focus on weight loss as the primary treatment for high blood pressure, high blood sugar, and high cholesterol. Instead of taking multiple medications for each issue, prioritize lifestyle changes or weight-loss medications to reduce body fat, as this addresses the root cause that drives all other metabolic risks.
The causal relationships overwhelmingly indicate that adiposity impels dysglycemia, HTN, and dyslipidemia... The tactical implication is that once a dominant driver is identified, then management can focus on that single driver derangement, in contrast to the conventional approach where any driver derangement, however numerous, would be managed concurrently and independently, presumably with more pharmacotherapy, cost, and risk.
Why this rating
Observational cohort study with strong mechanistic backing from cited literature, but lacks randomized controlled trial data for the specific 'dominant driver' protocol.
Source
The dominant driver paradigm of cardiometabolic care
Joel Hernandez Sevillano et al. · American Journal of Preventive Cardiology · 2025
DOI 10.1016/j.ajpc.2025.101389
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →